Valuation : Nurix Therapeutics, Inc.

Market Cap 2.73B 2.35B 2.21B 2.01B 3.76B 259B 3.78B 26.17B 10.11B 132B 10.23B 10.01B 419B P/E 2026 *
8.6x
P/E 2027 * -17.7x
Enterprise Value 1.78B 1.53B 1.44B 1.31B 2.46B 169B 2.47B 17.07B 6.6B 86.19B 6.68B 6.53B 273B EV / Sales 2026 *
2.35x
EV / Sales 2027 * 15.2x
Free-Float
98.67%
Yield 2026 *
-
Yield 2027 * -
1 day+0.50%
1 week+1.70%
Current month+1.86%
1 month+2.86%
3 months+67.90%
6 months+69.42%
Current year+38.43%
1 week 24.97
Extreme 24.97
26.7
1 month 24.95
Extreme 24.95
28.23
Current year 14.01
Extreme 14.01
28.23
1 year 8.2
Extreme 8.195
28.23
3 years 4.22
Extreme 4.22
29.56
5 years 4.22
Extreme 4.22
37.11
10 years 4.22
Extreme 4.22
52.38
Manager TitleAgeSince
Chief Executive Officer 64 2014-09-17
Director of Finance/CFO 60 2016-02-29
Chief Tech/Sci/R&D Officer - 2019-07-31
Director TitleAgeSince
Director/Board Member 64 2014-09-17
Chairman 73 2019-07-31
Chairman 73 2024-05-19
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 Exercice

Compliance Officer

17,361 0.0167%
9/1/26 Exercice

Chief Technology Officer

4,356 0.0042%
8/5/26 Exercice

Chief Technology Officer

13,068 0.0126%
Change 5-day change 1-year change 3-year change Capi.($)
+0.50%+1.70%+185.43%+177.88% 2.73B
-0.94%-0.71%+45.60%+103.25% 68.52B
-0.37%-5.50%+31.47%+75.35% 62.88B
+3.13%+1.71%-12.50%+390.48% 28.13B
-2.74%-6.55%+26.01%+10.96% 25.56B
-0.54%-5.47%-3.88%-18.31% 24.65B
-1.31%-4.05%+19.16%-18.67% 19.81B
-4.27%+3.07%+211.22%+362.48% 17.69B
-1.37%-4.71%-5.41%+506.15% 14.66B
+1.14%-0.34%+52.38%+163.82% 14.45B
Average -0.69%-1.30%+54.95%+175.34% 27.91B
Weighted average by Cap. -0.68%-1.83%+38.06%+139.53%

Financials

2026 *2027 *
Net sales 755M 650M 612M 558M 1.04B 71.87B 1.05B 7.25B 2.8B 36.62B 2.84B 2.77B 116B 121M 104M 97.85M 89.15M 167M 11.49B 167M 1.16B 448M 5.85B 453M 444M 18.55B
Net income 368M 317M 298M 272M 509M 35.03B 511M 3.54B 1.37B 17.85B 1.38B 1.35B 56.54B -174M -150M -141M -128M -240M -16.55B -241M -1.67B -645M -8.43B -653M -639M -26.71B
Net Debt -947M -815M -768M -699M -1.31B -90.15B -1.31B -9.1B -3.52B -45.93B -3.56B -3.48B -145B -885M -762M -717M -654M -1.22B -84.24B -1.23B -8.5B -3.29B -42.92B -3.32B -3.25B -136B
Logo Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, aimed at improving treatment options for patients with cancer and autoimmune diseases. The Company's wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company's portfolio of targeted protein degraders of the B‑cell signaling protein BTK comprises bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127). The Company's degradation inhibitor program includes NX-1607, an orally bioavailable inhibitor of CBL-B, an E3 ligase that regulates the activation of multiple immune cell types including T cells and NK cells. NX-1607 is targeted for immuno-oncology indications.
Employees
317
Date Price Change Volume
26-09-09 US$26.26 +0.50% 1,027,510
26-09-08 US$26.13 -0.04% 1,287,859
26-09-04 US$26.14 +3.24% 1,232,151
26-09-03 US$25.32 -1.94% 1,381,489
26-09-02 US$25.82 -0.84% 1,736,081
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
26.26USD
Average target price
33.93USD
Spread / Average Target
+29.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NRIX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!